GS vs INBX · P/E 20, rev $58.28B vs rev $1.3M
Goldman Sachs Group Inc (GS) versus Inhibrx Biosciences, Inc. (INBX) — a side-by-side from cached financials, not a winner call.
Goldman Sachs Group Inc (GS) is a capital markets company listed on NYSE. It is led by David M. Solomon.
Inhibrx Biosciences, Inc. (INBX) is a biotechnology company listed on US.
Latest reported GS revenue for 2025-12-31 was $58.28B. Net income was $17.18B. Revenue was up 8.9% from 2024-12-31 to 2025-12-31. GS currently screens at market cap $324.25B and trailing P/E 20.1.
Latest reported INBX revenue for 2025-12-31 was $1.3M. Net income was -$140.1M. Revenue was up 550.0% from 2024-12-31 to 2025-12-31. INBX currently screens at market cap $1.28B.
GS currently screens at market cap $324.25B and trailing P/E 20.1. INBX currently screens at market cap $1.28B.
Not investment advice. Open the GS and INBX stock pages for the full models.
Not investment advice.